Article
Circulating tumor DNA and radiological tumor volume identify patients at risk for relapse with resected, early-stage non-small-cell lung cancer.
Annals of oncology : official journal of the European Society for Medical Oncology - 1 Feb 2024
Tran H T, Heeke S, Sujit S, Vokes N, Zhang J, Aminu M, Lam V K, Vaporciyan A, Swisher S G, Godoy M C B, Cascone T, Sepesi B, Gibbons D L, Wu J, Heymach J V
Abstract excerpt
BACKGROUND: Predicting relapse and overall survival (OS) in early-stage non-small-cell lung cancer (NSCLC) patients remains challenging. Therefore, we hypothesized that detection of circulating tumor DNA (ctDNA) can identify patients with increased risk of relapse and that integrating radiological tumor volume measurement along with ctDNA detectability improves prediction of outcome. PATIENTS AND METHODS: We...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.